Memantine Treatment for Moderate to Severe Alzheimer's Disease

Clinical Efficacy

Memantine improves cognition and global assessment in moderate to severe Alzheimer's disease, though the magnitude of effect may not reach clinical significance in all domains 1
Studies demonstrate statistically significant improvements on the Severe Impairment Battery (SIB) and CIBIC-plus scale for patients with moderate to severe Alzheimer's disease 2
Memantine shows benefits in quality of life, with less agitation reported in treatment groups compared to placebo 1

Combination Therapy

Memantine can be used as monotherapy or in combination with cholinesterase inhibitors 3
Combination therapy with memantine plus a cholinesterase inhibitor has shown superior outcomes compared to cholinesterase inhibitor therapy alone 2

Adverse Effects

Withdrawal rates due to adverse effects range from 9-12% in treatment groups (compared to 7-13% in placebo groups) 2

Treatment Duration and Discontinuation

Consider discontinuation if clinically meaningful worsening of dementia occurs over 6 months without other contributing factors 2
Consider discontinuation if no clinical benefit is observed during treatment 2
Consider discontinuation if the patient progresses to severe or end-stage dementia with dependence in most basic activities of daily living 2
When discontinuing, use a gradual approach, reducing dose by 50% every 4 weeks until reaching the initial starting dose 3, 2

Important Clinical Considerations

For patients with neuropsychiatric symptoms (psychosis, agitation, aggression), continue memantine if there has been a clinically meaningful reduction in these symptoms, even with cognitive and functional decline 2

Combination Therapy for Alzheimer's Disease

Efficacy of Combination Therapy

The combination of donepezil and memantine is effective in patients with moderate to severe Alzheimer's disease, leading to significant improvements in cognition, daily functioning, and behavioral symptoms, as recommended by the American Academy of Neurology 4

Safety and Tolerability

The combination of donepezil and memantine is well-tolerated, with memantine being well-tolerated both as monotherapy and in combination with donepezil, according to the American Geriatrics Society 4

Combination Therapy for Moderate to Severe Alzheimer's Disease

Efficacy Benefits

The combination of memantine and donepezil produces significant benefits on global clinical status measures in patients with Alzheimer's disease, as noted by the American Academy of Neurology 5, 6
Patients on combination therapy show improvements in neuropsychiatric symptoms and reduced caregiver distress, particularly at 12 weeks of treatment 7, 8

Clinical Trial Evidence

Adding memantine to stable donepezil therapy provides additional benefit in patients with moderate to severe Alzheimer's disease, with a standardized mean difference of 0.36 for cognition 5

Safety Profile

The combination of memantine and donepezil is well-tolerated with no significant increase in serious adverse events, and adverse event rates are similar between combination therapy and monotherapy groups 9

Combination Therapy for Alzheimer's Disease

Disease Stage-Specific Recommendations

The American College of Physicians recommends starting with donepezil alone at 5 mg daily in the evening, taken with food, for mild to moderate Alzheimer's disease, with an increase to 10 mg daily after 4-6 weeks if tolerated, as donepezil shows consistent evidence of improving cognition and global function in this population, with a cognitive benefit averaging 2.02 points on ADAS-cog at 24 weeks for 5 mg dose and 2.92 points for 10 mg dose 10
For moderate to severe Alzheimer's disease, the American Geriatrics Society supports the use of combination therapy with both donepezil and memantine, as this recommendation is supported by guidelines from the US, China, and Japan, and the combination produces significantly better outcomes than donepezil monotherapy across all domains 11

Adverse Effects

Donepezil causes primarily gastrointestinal side effects, such as nausea, vomiting, diarrhea, and anorexia, more common with 10 mg dose, with low withdrawal rates due to adverse effects 10
Memantine has withdrawal rates of 9-12%, similar to placebo, with common side effects including nausea, dizziness, diarrhea, and agitation, though memantine may actually reduce agitation 12
The combination of donepezil and memantine is well-tolerated, with no significant increase in serious adverse events, and memantine shows particular benefit for behavioral symptoms and caregiver distress at 12 weeks 13

Combination Therapy for Moderate-to-Severe Alzheimer's Disease

Rationale for Adding Memantine to Donepezil

The American Academy of Family Physicians recommends that sertraline is not indicated for cognitive decline in Alzheimer's disease, and there is no evidence to support its use in this context 14
The American Academy of Family Physicians and the Annals of Internal Medicine suggest that adding a second cholinesterase inhibitor to donepezil is not evidence-based and would increase cholinergic side effects without additional benefit, and that switching between cholinesterase inhibitors is only considered when patients fail to respond to or cannot tolerate the first agent 14, 15

Safety Considerations

The American Academy of Family Physicians notes that donepezil side effects can be minimized by taking with food, and that monitoring for gastrointestinal effects (nausea, vomiting, diarrhea) is necessary 14

Monitoring and Duration

The American Academy of Family Physicians recommends assessing response at 12 and 24 weeks using cognitive measures and functional assessments 14

Evidence for Memantine and Donepezil on Behavioral Symptoms in Alzheimer’s Disease

Evidence Quality and Limitations

Behavioral and quality‑of‑life outcomes were assessed in relatively few trials and demonstrated inconsistent effects across studies of mild‑to‑moderate Alzheimer’s disease, most of which lasted only 6 months【16】. (Evidence quality: low)
The majority of available studies focused on patients with mild‑to‑moderate disease and had a maximum follow‑up of 6 months, limiting conclusions about long‑term behavioral benefits【17】. (Evidence quality: low)

Memantine – Agitation‑Specific Benefits

Across multiple randomized trials, memantine significantly reduced the frequency of agitation compared with placebo in patients with Alzheimer’s disease【18】. (Evidence quality: moderate)
The agitation‑reducing effect of memantine was confirmed in additional independent studies, reinforcing its efficacy for this symptom【19】. (Evidence quality: moderate)

Safety and Tolerability of Memantine

Memantine was well tolerated both as monotherapy and when combined with donepezil, with adverse‑event–related withdrawal rates (9‑12 %) comparable to placebo (7‑13 %)【18】. (Evidence quality: moderate)
Common side effects reported with memantine included mild gastrointestinal symptoms, dizziness, and headache, but these did not lead to higher discontinuation than placebo【19】. (Evidence quality: moderate)

Memantine Use and Hypertension Risk

Clinical Trial Safety at Therapeutic Doses

In randomized trials of older adults with moderate‑to‑severe Alzheimer’s disease, withdrawal because of adverse effects occurred in 9–12% of participants receiving memantine versus 7–13% of those receiving placebo, indicating no excess discontinuations attributable to memantine 20.
The most frequently reported adverse events in these trials were gastrointestinal symptoms (approximately 4–18% of participants), dizziness (6.1% with memantine vs 3.9% with placebo), headache (5.5% vs 4.3% with placebo), and agitation (4–18%; memantine actually showed a protective effect against agitation compared with placebo) 20.
At standard therapeutic regimens (20 mg/day oral or 28 mg extended‑release), hypertension is not identified as an expected adverse effect of memantine 20.

Evaluation When Hypertension Appears in a Patient on Memantine

If a patient on memantine develops hypertension, clinicians should assess for progression of underlying vascular disease and for potential drug‑drug interactions, as recommended by the American Geriatrics Society 21.
The American Geriatrics Society guidelines illustrate that polypharmacy can produce multifactorial cardiovascular effects; for example, a patient receiving both metoprolol and donepezil experienced bradycardia, highlighting the need to consider interactions when new hypertension or other hemodynamic changes arise 21.

Safety and Tolerability of Donepezil and Memantine in Alzheimer’s Disease

Overall Tolerability

In elderly patients with Alzheimer’s disease, both donepezil and memantine are generally well‑tolerated; donepezil’s most frequent adverse events are gastrointestinal (nausea, vomiting, diarrhea) and bradycardia, whereas memantine shares similar gastrointestinal symptoms and additionally may cause dizziness and headache, but it appears to reduce agitation rather than provoke it. 22, 23, 24

Donepezil‑Specific Adverse Effects

Gastrointestinal side effects – nausea, vomiting, and diarrhea are common with donepezil therapy. 22, 23
Cardiac effect – bradycardia occurs in a notable minority of patients receiving donepezil. 22, 23
Neuropsychiatric effect – nightmares have been reported in patients treated with donepezil. 22, 23

Memantine‑Specific Adverse Effects

Gastrointestinal side effects – memantine is associated with nausea, vomiting, and diarrhea in a proportion of treated individuals. 24
Behavioral effect – although agitation is listed as a possible side effect, randomized trials demonstrate that memantine provides a protective effect against agitation compared with placebo. 24

Withdrawal Due to Adverse Events

Memantine – discontinuation rates attributable to adverse events range from 9 % to 12 % in memantine groups, which is comparable to 7 % to 13 % observed with placebo, indicating no excess discontinuations caused by the drug. 24